Reference guide for mRNA capping (Cap 0/1/2, ARCA, CleanCap), terminal phosphate states (ppp/pp/p), NAD caps, and key 3′ RNA caps. Designed for therapeutic mRNA, vaccines, CRISPR guides, and innate-immunity studies.
5′ caps protect RNA from exonucleases and tune translation and innate sensing. Cap 1 is standard for therapeutic mRNA, while 5′-triphosphate RNA (pppRNA) is intentionally used to activate RIG-I in immunology. Non-canonical caps such as 5′-NAD appear in bacteria and can be leveraged in synthetic biology. At the 3′ end, cyclic- and mono-phosphate caps modulate ligation and stability workflows.
m⁷G caps (Cap 0/1/2) increase 5′ stability and translation efficiency.
ppp/pp RNA triggers RIG-I; Cap 1 reduces innate sensing for in vivo use.
Co-transcriptional reagents (CleanCap™) and ARCA simplify GMP workflows.
Canonical eukaryotic-style caps supporting translation and stability. Choose Cap 1 for most therapeutic programs; Cap 2 can further reduce innate sensing in some systems.
Uncapped or processed 5′ ends used for innate-immunity probes or enzymology workflows.
Alternative metabolites used as 5′ caps in bacteria/archaea or synthetic biology contexts.
NAD capping can alter degradation pathways; evaluate compatibility with ligases and cap-binding proteins prior to workflow design.
Common 3′ terminal states used for stability or library construction.
IVT mRNA, sgRNA, capped & tailed, dsRNA controls.
Microfluidic LNP for mRNA/siRNA with QC and release testing.
Capping efficiency, dsRNA assays, HPLC, LC-MS, endotoxin.
Cap 1 is the default for human therapeutics. Test Cap 2 if innate sensing remains elevated or in specific cell types where additional 2′-O-methylation helps.
Yes, for RIG-I activation studies. For any therapeutic product, remove ppp (or re-cap) to reduce immunogenicity and increase stability
Yes. 2′,3′-cPO₄ requires RTCB-type ligases; convert to 3′-OH for standard T4 ligase reactions.
We’ll recommend capping, end-state conversions, and QC panels aligned to your delivery and indication.
Tell us about your RNA capping project
Please avoid confidential details; we can arrange an NDA if needed.
JavaScript is disabled. The Email button above will open your email client to contact info@biosyn.com.
Trusted by biotech leaders worldwide for over 40+ years of delivering high quality, fast and scalable synthetic biology solutions.